The analysis of rare chromosomal translocations in myeloproliferative disorders has highlighted the importance of aberrant tyrosine kinase signalling in the pathogenesis of these diseases. Here we have investigated samples from 679 patients and controls for the non-receptor tyrosine kinase JAK2 V617F mutation. Of the 480 MPD samples, the proportion of positive cases per disease subtype was atypical or unclassified MPD 30/152 (20%), idiopathic hypereosinophilic syndrome 2/134 (2%), polycythemia vera 58/72 (81%), essential thrombocythemia 24/59 (41%) and idiopathic myelofibrosis 15/35 (43%). V617F was not identified in patients with systemic mastocytosis (n=28), chronic or acute myeloid leukemia (n=35), secondary erythrocytosis (n=4) or normal controls (n=160). Homozygosity for V617F was seen in 43% of mutant samples and closely correlated with chromosome 9p uniparental disomy. Homozygosity was significantly less common in ET compared to other MPD subtypes. In 53 cases analysed, the median level of PRV1 expression was significantly higher in V617F positive cases compared to cases without the mutation. We conclude that V617F is widespread in MPDs. Detection of this acquired mutation is likely to have a major impact on the way MPD patients are diagnosed, as well as serving as an obvious target for signal transduction therapy.
Introduction
Chronic myeloproliferative diseases (CMPDs) are clonal hematopoietic stem cell disorders characterized by proliferation of one or more myeloid cell lineages in the bone marrow and increased numbers of mature and immature cells in the peripheral blood. CMPDs include polycythemia vera (PV), essential thrombocythemia (ET), idiopathic myelofibrosis (IMF) and chronic myeloid leukemia (CML), plus rarer subtypes such as chronic neutrophilic leukemia (CNL), hypereosinophilic syndrome (HES) and chronic eosinophilic leukemia (CEL). These diseases overlap with myelodysplastic/myeloproliferative diseases (MDS/MPD) such as atypical CML (aCML) and chronic myelomonocytic leukemia (CMML), in which proliferation is accompanied by dysplastic features or ineffective hemopoiesis in other lineages. 1 We refer here broadly to all these groups as myeloproliferative disorders (MPDs).
Although there are strict diagnostic criteria for MPD subtypes, precise categorisation remains a subject of debate 2 and furthermore it can be difficult to differentiate some cases from reactive disorders. Only CML is characterized by a pathognomonic molecular marker, the BCR-ABL fusion, and the primary abnormalities driving excess proliferation in most other cases have been obscure. However several lines of evidence have implicated aberrant tyrosine kinase signalling as the root cause of MPDs. BCR-ABL itself is a constitutively active tyrosine kinase that is believed to be the primary, and probably the only, driving force behind chronic phase CML. 3 Other gene fusions have been identified in rare cases of aCML, CMML and HES/CEL that involve the tyrosine kinases PDGFRA, PDGFRB, FGFR1 and JAK2. 4, 5 The KIT receptor is activated by point mutation in the majority of cases of systemic mastocytosis, a disease that is classified separately by the World Health Organisation but which is clearly myeloproliferative in nature. 1, 6 For personal use only. on September 14, 2017 . by guest www.bloodjournal.org From Observations in other MPD subtypes have also implicated aberrant signalling in their pathogeneis, albeit indirectly. Myeloid cells from patients are hypersensitive to a number of growth factors and cytokines, with PV and IMF in particular being characterized by the presence of erythroid and megakaryocytic precursor cells, respectively, that grow spontaneously in culture. [7] [8] [9] [10] This factor independent growth and/or terminal differentiation can be blocked by a range of signal transduction inhibitors. 11, 12 Finally, some patients show increased expression of the anti-apoptotic factor Bcl-XL and activation of STAT3 or STAT5, 11, 13, 14 all of which are downstream elements of tyrosine kinase signalling. To investigate the molecular pathogenesis of
MPDs we therefore initiated a mutation screen for genes encoding tyrosine kinases and downstream signalling components.
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Methods

Patients
We studied samples from a total of 679 individuals. Of these, 480 were patients with a known or suspected diagnosis of an MPD (268 males, 212 females) referred for analysis in Athens, Mannheim or Salisbury. Patients were referred for PV (n=72, including one case who also had systemic mastocytosis), ET (n=59), IMF (n=35), idiopathic HES (n=134), systemic mastocytosis (n=28), CML-like diseases (aCML, CMML and related atypical MPDs, n=99) or atypical, unclassified MPD (n=53). All HES, systemic mastocytosis, CML-like diseases and atypical, unclassified MPD cases were tested for BCR-ABL, FIP1L1-PDGFRA, KIT D816V (mastocytosis cases only) and other gene fusions as indicated by karyotype. None were BCR-ABL positive but 24 had rare tyrosine kinase fusion genes involving PDGFRA, PDGFRB, FGFR1 or JAK2 and 8 had the KIT D816V mutation. We also studied samples from patients with AML (n=17), BCR-ABL positive CML (n=18) plus controls from normal individuals (n=160) or individuals with secondary erythrocytosis (n=4). The study was approved by the Internal Review Boards from participating institutions and informed consent was provided according to the Declaration of Helsinki.
Mutation screening
Initially, we studied a set of 40 atypical, CML-like MPD patients by heteroduplex analysis (either denaturing high performance liquid chromatography or conformation sensitive capillary electrophoresis) to screen candidate genes encoding tyrosine kinase and downstream signalling components for mutations. We focused on known mutational hotspots seen in other malignancies [11] [12] [13] [14] , but no abnormalities were detected apart from known polymorphisms. All exons of HRAS, KRAS and NRAS were also screened and five cases (12.5%) were found to have activating mutations of NRas (G12S, n=2; G12D, n=1; G12C, n=1, G13S, n=1). PCR primer sequences and assay conditions are available on request. Following the recent report of the JAK2 V617F mutation (2343G>T; JAK2 exon 12; RefSeq ID NM_004972; www.ensembl.org) in patients with PV, ET and IMF, [15] [16] [17] [18] we focused specifically on this abnormality.
V617F genotyping by amplification refractory mutation system (ARMS)
DNA was extracted by standard procedures after isolation of total leukocytes from peripheral blood following red cell lysis or mononuclear cells by density gradient centrifugation over
Histopaque 1077 (Sigma-Aldrich, Ayrshire, UK). Patients and controls were genotyped initially by a DNA tetra-primer ARMS assay, a method that employs two primer pairs to specifically amplify the normal and mutant sequences plus a positive control band in a single reaction. 
V617F genotyping and allele quantitation by Pyrosequencing
DNA samples were amplified using primers 5'-biotin-GAAGCAGCAAGTATGATGAGCA-3' (forward; JAK2 exon 12) and 5'-TGCTCTGAGAAAGGCATTAGAA-3' (reverse; JAK2 intron 12). Amplicons were generated in a 50µl reaction volume with 15pmol of forward and reverse PCR primers, 0.2mM dNTPs (Promega, Southampton, UK), 1.5mM MgCl 2 , 1xBuffer II (Applied Biosystems, Warrington, Cheshire, UK), 1U AmpliTaq Gold (Applied Biosystems) using 10ng genomic DNA. PCR conditions were 94°C for 7 min; 50 cycles with denaturation at 94°C for 30s, annealing at 58°C for 30s and elongation at 72°C for 30s; 1 cycle at 72°C for 7 min; and a final hold at 15°C. Single-stranded biotinylated PCR products were prepared for sequencing using the Pyrosequencing™ Vacuum Prep Tool. 3µl Streptavidin Sepharose™ HP (Amersham Biosciences, Chalfont St. Giles, UK) was added to 37µl Binding buffer (10 mM Tris-HCl pH 7.6, 2M NaCl, 1 mM EDTA, 0.1% Tween 20) and mixed with 20µl PCR product and 20µl high purity water for 10 min at room temperature using a Variomag Monoshaker (Camlab, Over, UK).
The beads containing the immobilised templates were captured onto the filter probes after Products were analysed on an ABI 3100 genetic analyser using the program Genotyper 2.0. Peak heights were compared to controls and scored as heterozygous for each marker if there were two clear peaks of similar intensity, or the ratio of the two peaks were similar to normal controls.
Patients were scored as homozygous if only one peak was visible or, to allow for the presence of background normal cells, if one peak was one third or smaller than the expected size compared to controls. UPD was scored if four or more consecutive markers abutting or encompassing JAK2
were homozgygous (P<0.05 of this occurring in the absence of UPD based on published rates of heterozygosity; www.gdb.org).
Copy number determination by multiplex ligation probe amplification (MLPA)
MLPA primers were designed to non-polymorphic exons of 21 with the PCR products being separated on an ABI 3100 genetic analyser. Peak areas were exported to an Excel spreadsheet, which was designed to assess the ratios of each test peak relative to all other peaks for that individual. Ratios of the JAK2 peak to other peaks in each patient sample were compared to the same ratios obtained for two normal individuals which were included in each run. For normal sequences a dosage quotient of 1.0 is expected; if a deletion or duplication is present the dosage quotient should be 0.5 and 1.5, respectively. 22 BTK is on the X-chromosome and therefore provided an internal control that the assay was working (dosage quotient of 0.5 in males and 1.0 in females).
Statistical analysis
Observed and expected frequencies were compared by χ 2 analysis. Mutation status was compared to PRV1 mRNA levels using the Mann-Whitney test.
Results
Incidence of V617F JAK2
Of the 480 samples with a known or suspected diagnosis of an MPD, 129 (27%) were positive for the V617F JAK2 mutation by the ARMS assay and 351 (73%) were negative. Representative results are shown on Figure 1a . Sequence analysis of selected cases (n=51) was fully concordant with the ARMS results (Figure 2a) , although in some cases the proportion of the mutant allele was low and would have been difficult or impossible to detect by sequence analysis alone.
Analysis of a dilution series indicated the sensitivity of the ARMS assay to be 1-2% (Figure 1b ), whereas sequencing is generally accepted to have a sensitivity of only 20-30%, depending on the sequence context.
Using the ARMS assay, we found that the proportion of positive cases per disease subtype ranged from 58/72 (81%) for PV to 0/28 (0%) for mastocytosis (Table 1) . Strikingly, V617F was detected in a substantial proportion of patients with CML-like diseases and atypical, unclassified MPD. V617F was not detected in any of the 480 MPD cases with rare tyrosine kinase fusion genes (n=24), nor in any individual with CML (n=18), AML (n=17) or in healthy controls (n=160). V617F and KIT D816V was found in one individual who had both PV and systemic mastocytosis, but not in any of the other seven D816V positive cases. Of the 14 V617F mutation negative PV patients, 13 were male (P=0.005, χ 2 ) but no other significant associations between sex and mutation status were identified. Mutation analysis of JAK2 exon 12 in V617F negative cases did not reveal any additional sequence variants.
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Relative ratios of V617F and normal JAK2 alleles
The ARMS and sequencing results for several patients showed mutant bands much stronger than the wild type bands (Figure 1a, 2a) and in some cases the wild type band was not visible at all, suggesting that the mutation may be homozygous in the mutant clone. Since ARMS and sequencing results are not always quantitative, we designed a Pyrosequencing assay for the V617F mutation, as this method is capable of providing robust allele ratios. 23 Pyrosequencing was performed on the 90 mutant samples for which DNA was available, and confirmed homozygosity in most of the samples with a stronger mutant band by ARMS analysis ( Figure   2b ). Samples analysed by ARMS only were therefore scored as homozygous if the ratio mutant/wild type bands was at least as strong as that seen in the 50% dilution control (Figure 1b 
V617F and chromosome 9p uniparental disomy
A homozygous V617F clone was seen in 24/72 (33%) cases of PV, 4/59 (7%) cases of ET, and 10/35 (29%) cases of IMF. This is strikingly similar to the frequencies of acquired chromosome 9p uniparental disomy (UPD; autosomal regions for which both copies are derived from a single parent) that has been described in these diseases. Furthermore, the minimal disomic region contains JAK2. 24, 25 To determine if UPD9 was associated with homozygosity for V617F, we initially performed microsatellite analysis on 57 cases (normal, n=30; V617F homozygous, n=27). Microsatellites were scored as homozygous or heterozygous and the results are summarised on Figure 3 . In normal individuals, most microsatellites are expected to be heterozygous. Consecutive tracts of homozygous markers usually indicate loss of heterozygosity (LOH) due to complete or partial chromosome loss, or UPD. We found significant tracts of homozygosity in the vicinity of JAK2 in 4 (13%) of the normal cases and 25 (93%) of the V617F homozygotes (P<0.0001). To determine whether this homozygosity arose through LOH or UPD,
we measured the number of copies of the JAK2 gene relative to control genes by MLPA. One copy of JAK2 would indicate LOH, whereas two copies would indicate UPD. All seven cases analysed that were homozygous for both V617F and at least three consecutive 9p markers had two copies of JAK2, consistent with UPD9 ( Figure 4a) .
Correlation between the presence of V617F and overexpression of PRV1
Overexpression of the PRV1 gene has been reported in the great majority of patients with PV and a subset of patients with ET and IMF. [26] [27] [28] [29] Although the mechanism of overexpression is not known, many groups consider quantification of PRV1 mRNA to be a useful supplementary test in the diagnosis of MPDs. To determine if PRV1 expression is associated with abnormalities of
For personal use only. on September 14, 2017. by guest www.bloodjournal.org From JAK2, we compared mRNA levels to mutational status in 53 cases (PV, n=15; ET, n=32; IMF, n=6). Although there was considerable overlap between the range of PRV1 levels in normal JAK2 (n=30, median = 293, range = 6 -17,500) and V617F cases (n=23, median = 2700, range = 59 -208,000), the difference between the two groups was significant (P=0.0004, Mann-Whitney test).
The median PRV1 level for homozygous V617F cases (median = 4940, n=11) was greater than the median for heterozygous cases (median = 1650, n=12), but the difference was not significant (P= 0.1, Mann-Whitney). Results are summarised in Figure 4b .
Discussion
We have identified the JAK2 V617F mutation in approximately one fifth of patients with an atypical MPD, as well as confirming the presence of this mutation in the great majority of patients with PV and nearly half of cases with ET or IMF. The finding of an identical mutation in such clinically diverse (although clearly related) cases is quite remarkable. There is nothing in the sequence context to suggest that position 2343G might be particularly mutable and, since no other mutations were found in JAK2 exon 12, it seems likely that the V617F substitution must have very specific functional consequences. The mutation occurs in a highly conserved region of the pseudokinase (JH2) domain, a region that is homologous to the true tyrosine kinase domain but lacks key catalytic residues, and has been shown to constitutively activate JAK2. 15, 16, 18 The pseudokinase domain is believed to negatively regulate JAK2 signalling by direct interaction with the kinase domain. 30 Structural modelling has suggested that residues V617 to E621 form a loop connecting two β-strands of the N-terminal lobe of the pseudokinase domain, with C618
For personal use only. on September 14, 2017. by guest www.bloodjournal.org From contacting the kinase activation loop. It has been postulated that V617, C618 and other local residues inhibit movement of the activation loop from its inactive to its active conformation, 31 ie.
the V617 region plays a direct role in negatively regulating JAK2 signalling. The substitution of V617 by the large aromatic amino acid phenylalanine is likely to disrupt this negative regulation, although this remains to be proven biochemically. However, evidence that amino acid substitutions in the pseudokinase domain can activate JAK2 comes from the Drosophilia mutation hopscotch, in which a mutation corresponding to E695K in the human protein results in hematopoietic hyperplasia. 32 In addition, JAK2 has been directly implicated in human malignancy, first by fusion to TEL/ETV6 and PCM1 as a consequence of chromosome translocations in leukemia [33] [34] [35] and, second, by aberrant signalling in a wide range of solid tumours.
36
JAK2 is a non-receptor tyrosine kinase that plays a major role in myeloid development by transducing signals from diverse cytokines and growth factor receptors, including those for IL-3, IL-5, erythropoietin, GM-CSF, G-CSF and thrombopoietin. 36, 37 It seems likely that a mutation which interferes with the negative regulation of JAK2 could account for the observed hypersensitivity of myeloid cells from MPD patients to growth factors. However it is not clear why different individuals with V617F show preferential expansion of erythroid, granulocyte, megakaryocyte, monocyte or eosinophil lineages. Potentially, this could be due to the identity of the cell in which the mutation arises, the constitutional genetic background of the individual or to other, secondary acquired changes.
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In addition to secondary or constitutional differences, V617F itself may also play a role in specifying disease phenotype since we found homozygosity to be significantly less common in ET compared to other MPD subtypes. However definitive identification of V617F copy number in individual cases is complicated by the fact that it is not possible to distinguish between a relatively small homozygous clone and a larger heterozygous clone when mixed populations of cells are analyzed. Nevertheless, we found a wide range (5-100%) in the relative proportion of mutant alleles in V617F positive cases by Pyrosequence analysis. The fact that (i) the mutation was present at a level substantially less than the wild type allele in many heterozygous cases, (ii) the wild type allele was detectable in the great majority of homozygous patients and (iii) the age of homozygous cases (median = 63 years, range 17-69) was not significantly different from heterozygous cases (median = 62 years; range 5-88) strongly suggests that the mutation was acquired. Other studies have shown that V617F is absent in T-cells and the great majority of buccal epithelial samples, clearly indicating that the mutation was acquired in these individuals. [15] [16] [17] [18] However we cannot exclude the possibility that V617F might be inherited in occasional cases, although this seems unlikely as linkage to chromosome 9p has been excluded in MPD families. 27, 38 Although V617F accounts for an important subset of cases with CML-like diseases and atypical MPDs, the pathogenesis of the majority of these cases remains unknown. In our original series of 40 CML-like cases, only one third of those that were negative for rare tyrosine kinase fusion genes were found to have the V617F JAK2 mutation or an activating N-RAS mutation (no case had a JAK2 and RAS mutation). PV and IMF are both considered to be clonal diseases,
suggesting that the molecular basis of roughly 20% and 60%, respectively, of these diseases
For personal use only. on September 14, 2017 . by guest www.bloodjournal.org From remain to be elucidated. However these figures may be overestimates since it is likely that some of the cases in our study had an unrecognized reactive condition. It is known that the clinical diagnostic precision varies between clinicians and it is possible therefore that the true incidence of V617F in PV and IMF is somewhat higher than we found in this study. 39 On the other hand, it is likely that technical differences relating to the sensitivity of V617F detection are also a contributory factor to the published differences in the proportions of positive cases within MPD subtypes. As for ET, approximately half of cases have clonal disease and half are polyclonal, and therefore presumably reactive. 40 Although we did not perform clonality assays, we found the V617F mutation in 41% of ET cases, suggesting that the great majority of clonal ET is V617F
positive. We did not observe V617F in patients with CML or AML, however the numbers of cases analysed were relatively small and therefore we cannot exclude the possibility that a small subset of cases might carry this mutation. Interestingly, 6 of the patients in our series had chronic neutrophilic leukemia, two of which were V617F positive.
We found that homozygosity for V617F in all disease subtypes was closely associated with chromosome 9 UPD, confirming previous results and suggesting a selective advantage for two copies of mutant JAK2. 16 We also found significant 9p homozygosity in four MPD cases without V617F which could indicate a mutation in a different region of JAK2. Although gain of chromosome 9p is known to be associated with MPDs, [42] [43] [44] UPD for this region is much more common. Recently, UPD for diverse chromosomal regions has been identified in acute leukemia 44, 45 and, although most of these regions have not yet been associated with specific acquired mutations, it is possible that reduction of oncogenic mutations to homozygosity by cytogenetically cryptic mitotic recombination is widespread in malignancy.
The fact that V617F was found in the great majority of cells and was homozygous in many cases suggests that it is probably the primary abnormality driving myeloproliferation. As such, it is clearly a very attractive target for signal transduction therapy with small molecule inhibitors, although at the time of writing no clinically available JAK2 inhibitors have been described. JAK family members play a crucial role in the immune system, for example inherited JAK3 deficiency causes severe combined imunodeficiency, 46, 47 and JAK2 also plays an important role in cardiovascular signalling systems. 48 Development of inhibitors that inhibit V617F without undesirable side effects may therefore be challenging.
Diagnosis of MPDs is often complex, expensive and in the case of ET, based solely on exclusion criteria. Since the detection of acquired V617F is simple to perform and unambiguously establishes the presence of a clonal disorder, we believe that JAK2 mutation testing will rapidly become a frontline test for individuals with a suspected diagnosis of an MPD. (immediately abutting the site of the mutation) and the dispensation order GCAGCATAC was used (the two G's are internal controls that should give no peak, E and S indicate enzyme and substrate, respectively). In a normal individual (sequence CACATAC) the peak heights of the first C and A are similar. In a heteryzygous individual (sequence (C/A)ACATAC) the C peak is reduced in height and the A peak increased above all other peaks as both the mutant A and
For personal use only. on September 14, 2017. by guest www.bloodjournal.org From following A are being read in the same reaction. In a homozygous individual (sequence AACATAC) the first C peak is either much lower than the A peak (third trace) or, occasionally, absent (fourth trace). The ratio of the normal (C) and mutant (A) alleles is calculated by the Pyrosequencing SNP analysis software. 
